Literature DB >> 33386337

Site-Level Variation in the Characteristics and Care of Infants With Neonatal Opioid Withdrawal.

Leslie W Young1, Zhuopei Hu2, Robert D Annett3, Abhik Das4, Janell F Fuller5, Rosemary D Higgins6,7, Barry M Lester8, Stephanie L Merhar9,10, Alan E Simon11, Songthip Ounpraseuth2, P Brian Smith12, Margaret M Crawford4, Andrew M Atz13, Lesley E Cottrell14, Adam J Czynski15, Sarah Newman16, David A Paul17, Pablo J Sánchez18, Erin O Semmens19, M Cody Smith20, Christine B Turley21, Bonny L Whalen22, Brenda B Poindexter23, Jessica N Snowden24, Lori A Devlin25.   

Abstract

BACKGROUND AND OBJECTIVES: Variation in pediatric medical care is common and contributes to differences in patient outcomes. Site-to-site variation in the characteristics and care of infants with neonatal opioid withdrawal syndrome (NOWS) has yet to be quantified. Our objective was to describe site-to-site variation in maternal-infant characteristics, infant management, and outcomes for infants with NOWS.
METHODS: Cross-sectional study of 1377 infants born between July 1, 2016, and June 30, 2017, who were ≥36 weeks' gestation, with NOWS (evidence of opioid exposure and NOWS scoring within the first 120 hours of life) born at or transferred to 1 of 30 participating hospitals nationwide. Site-to-site variation for each parameter within the 3 domains was measured as the range of individual site-level means, medians, or proportions.
RESULTS: Sites varied widely in the proportion of infants whose mothers received adequate prenatal care (31.3%-100%), medication-assisted treatment (5.9%-100%), and prenatal counseling (1.9%-75.5%). Sites varied in the proportion of infants with toxicology screening (50%-100%) and proportion of infants receiving pharmacologic therapy (6.7%-100%), secondary medications (1.1%-69.2%), and nonpharmacologic interventions including fortified feeds (2.9%-90%) and maternal breast milk (22.2%-83.3%). The mean length of stay varied across sites (2-28.8 days), as did the proportion of infants discharged with their parents (33.3%-91.1%).
CONCLUSIONS: Considerable site-to-site variation exists in all 3 domains. The magnitude of the observed variation makes it unlikely that all infants are receiving efficient and effective care for NOWS. This variation should be considered in future clinical trial development, practice implementation, and policy development.
Copyright © 2021 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33386337      PMCID: PMC7780957          DOI: 10.1542/peds.2020-008839

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  4 in total

1.  Effects of Pharmacologic Treatment for Neonatal Abstinence Syndrome on DNA Methylation and Neurobehavior: A Prospective Cohort Study.

Authors:  Marie Camerota; Jonathan M Davis; Lynne M Dansereau; Erica L Oliveira; James F Padbury; Barry M Lester
Journal:  J Pediatr       Date:  2021-12-28       Impact factor: 4.406

2.  Assessing the Impact of Prenatal Medication for Opioid Use Disorder on Discharge Home With Parents Among Infants With Neonatal Opioid Withdrawal Syndrome.

Authors:  Rosalyn Singleton; Sara Rutz; Gretchen Day; Melissa Hammes; Amy Swango Wilson; Mary Herrick; Connie Mazut; Laura Brunner; Jennifer Prince; Christine Desnoyers; Jennifer Shaw; Matthew Hirschfeld; Heather Palis; Amanda Slaunwhite
Journal:  J Addict Med       Date:  2022-03-01       Impact factor: 4.647

Review 3.  Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants.

Authors:  Lori A Devlin; Leslie W Young; Walter K Kraft; Elisha M Wachman; Adam Czynski; Stephanie L Merhar; T Winhusen; Hendrée E Jones; Brenda B Poindexter; Lauren S Wakschlag; Amy L Salisbury; Abigail G Matthews; Jonathan M Davis
Journal:  J Perinatol       Date:  2021-09-23       Impact factor: 3.225

4.  Measuring and controlling medical record abstraction (MRA) error rates in an observational study.

Authors:  Maryam Y Garza; Tremaine Williams; Sahiti Myneni; Susan H Fenton; Songthip Ounpraseuth; Zhuopei Hu; Jeannette Lee; Jessica Snowden; Meredith N Zozus; Anita C Walden; Alan E Simon; Barbara McClaskey; Sarah G Sanders; Sandra S Beauman; Sara R Ford; Lacy Malloch; Amy Wilson; Lori A Devlin; Leslie W Young
Journal:  BMC Med Res Methodol       Date:  2022-08-15       Impact factor: 4.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.